cadherin-22 Inhibitors

Cadherin-22 inhibitors encompass a range of chemical compounds that act on specific signaling pathways, with the end result being a decrease in cadherin-22 activity. The primary pathways targeted by these inhibitors include the EGFR, ERK/MAPK, PI3K/AKT, JNK, and p38 MAPK pathways. A majority of these compounds, such as genistein, U0126, quercetin, LY294002, wortmannin, apigenin, resveratrol, and EGCG, act on the EGFR, ERK/MAPK, and PI3K/AKT pathways, which are critical signaling pathways that cadherin-22 is thought to interact with. By inhibiting these pathways, these compounds can effectively reduce the functional activity of cadherin-22.

Other inhibitors target different but related pathways. For example, PD98059 inhibits the MAPK pathway, SB203580 acts on the p38 MAPK pathway, and SP600125 hinders the JNK pathway. These pathways are believed to intersect withthe biochemical processes in which cadherin-22 is involved. Inhibiting these pathways can also result in decreased functional activity of cadherin-22. The last compound, curcumin, is unique in that it has the capability to impact both the JNK and p38 MAPK signaling pathways, further diversifying the range of pathways that can be targeted to inhibit cadherin-22 activity. This extensive variety of chemical inhibitors, each with distinct pathway targets, underscores the complex regulatory network that controls cadherin-22 activity.